SpringWorks Therapeutics, part of Merck KGaA, has received conditional marketing authorization from the European Commission for its drug EZMEKLY® (mirdametinib), marking the first approved treatment ...
This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. In 2024 Stephen Rich and his colleagues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results